Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks : A retrospective, observational, multicentre study by the Spanish Psoriasis Group
del Alcázar Viladomiu, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
López-Ferrer, Anna (Institut d'Investigació Biomèdica Sant Pau)
Martínez-Doménech, Álvaro (Hospital General Universitario de Valencia)
Ruíz Villaverde, Ricardo (Hospital Universitario San Cecilio (Granada))
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid))
Rocamora, V. (Hospital de Manacor)
Julià, M. (Hospital de Basurto (Bilbao, Biscaia))
Notario, J. (Hospital Universitari de Bellvitge)
Fernández-Freire, L. R. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Sahuquillo-Torralba, A. (Hospital Universitari i Politècnic La Fe (València))
Vidal, D. (Hospital de Sant Joan Despí Moisès Broggi)
Rivera, Raquel (Hospital Universitario 12 de Octubre (Madrid))
Carretero, G. (Hospital Universitario de Gran Canaria Dr. Negrín)
Mateu, A. (Hospital Universitari Doctor Peset (València))
De la Cueva, Pablo (Hospital Universitario Infanta Leonor)
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Fecha:	2021
Resumen:	Data on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been published on the effectiveness and safety of guselkumab in the treatment of psoriasis in clinical practice. The ojective of this study was to assess the effectiveness and safety of guselkumab at 24 weeks in patients with moderate to severe plaque psoriasis in routine clinical practice. A retrospective, multicentre study of adult patients with moderate to severe plaque psoriasis treated with guselkumab for at least 24 weeks was carried out in Spain. We studied 343 patients, 249 of whom were followed for 24 weeks. By week 24, the mean (SD) psoriasis area severity index (PASI) had decreased from 11. 1 (7. 3) to 1. 7 (2. 8) (−9. 3; [−10. 2;-8. 4]), 85. 9% of the patients had achieved PASI score of 4 or less and 77. 9% a PASI score of 2 or less. In terms of relative PASI response, 59. 4% of the patients achieved a PASI-90 response and 49. 0% a PASI-100 response. On multivariate analysis, two factors reduced the probability of a PASI of 2 or less at 24 weeks: a BMI ≥30 (OR, 0. 44; 95% CI, 0. 22-0. 88) and a greater previous exposure to biologic therapy (OR, 0. 69; 95% CI, [0. 56-0. 84]). Adverse events were rare (9. 9%) and led to withdrawal from treatment in only nine patients (2. 6%) by the end of the follow-up period. The results of this study confirm the high efficacy and safety of guselkumab indicated by the clinical trial data. In clinical practice, the absolute PASI score appears to be a better marker of response to treatment than the relative value.
Nota:	Altres ajuts: acords transformatius de la UAB
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Guselkumab ; Psoriasis ; Real-world
Publicado en:	Dermatologic therapy, 2021 , ISSN 1529-8019

DOI: 10.1111/dth.15231
PMID: 34820971

10 p, 2.1 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados